Cirugía y Cirujanos

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Cirugía y Cirujanos >Year 2007, Issue 3

Ruiz-Molina JM, Ochoa-Sánchez EP, López-Basave HN, Barrera-Franco JL, Crocifoglio-Vincenzo A, Medina-Castro JM
Open splenectomy: Ten-year experience in an oncological referral center
Cir Cir 2007; 75 (3)

Language: Español
References: 24
Page: 163-168
PDF: 67.47 Kb.

[Full text - PDF]


Background: Open splenectomy is a useful procedure for some diseases with splenomegaly › 1500 g. We undertook this study to evaluate open splenectomy morbidity and mortality at the Instituto Nacional de Cancerologia in Mexico City.
Methods: We reviewed the clinical files of patients with benign and malignant hematological diseases, as well as other diseases, who underwent splenectomy from 1994 to 2005.
Results: Twenty five patients with a mean age of 38.5 years were submitted for open splenectomy. Splenomegaly was found in 12 patients (48 %). The most frequent abdominal wall incision was transverse left subcostal (64 %). Average surgical time was 125 min, bleeding 485 ml, spleen weight 1553.6 g and mean size 15 ´ 11 ´ 12 cm. Mean hospital stay was 7.5 days. Eighteen patients (72 %) did not have immediate complications. One patient (4 %) developed surgical wound infection, two patients (8 %) had significant pain, three patients (12 %) had bleeding and one patient (4 %) developed intraabdominal fluid collection. Twenty one patients (84 %) did not have further complications. One patient (4 %) developed multiple organ failure, another patient (4 %) developed thrombocytopenia and another (4 %) developed severe pain. During an average 81-month follow-up we found 14 patients (56 %) asymptomatic, two patients (8 %) with documented tumoral activity (angiosarcoma and non-Hodgkin’s lymphoma) and one patient (4 %) developed a second neoplasm. Six patients (2 %) died due to underlying disease (chronic myeloid leukemia and lymphoma), one patient (4 %) with active disease (Hodgkin’s disease) and one patient (4 %) died due to other causes.
Conclusions: With a spleen › 1500 g, open surgery offers better visibility and, in fact, less morbidity and mortality.

Key words: Open splenectomy.


  1. Rosen W, Brody F, Walsh M, Tarnoff M, Malf J, Ponsky J. Outcome of laparoscopic splenectomy based on hematologic indication. Surg Endosc 2002;16:272-279.

  2. 2. Sutherland GA, Burghard FF. The treatment of splenic anemia by splenectomy. Lancet 1916;2:1819-1822.

  3. 3. Friedman RL, Fallas MJ, Carroll BJ, et al. Laparoscopic splenectomy for ITP. The gold standard. Surg Endosc 1996;10:991-995.

  4. 4. Schwartz SI. Role of splenectomy in hematologic disorders. World J Surg 1996;20:1156-1159.

  5. 5. Berman R, Yahanda A, Mansfield P, et al. Laparoscopic splenectomy in patients with hematologic malignancies. Am J Surg 1999;178:530-536.

  6. 6. Horowitz J, Smith J, Weber T, et al. Postoperative complications after splenectomy for hematologic malignancies. Ann Surg 1996;223:290-296.

  7. 7. Brunt M, Langer J, Quasebarth M, et al. Comparative analysis of laparoscopic versus open splenectomy. Am J Surg 1996;172:596-601.

  8. 8. Tagarona E, Espert J, Balagué C, et al. Splenomegaly should not be considered a contraindication for laparoscopic splenectomy. Ann Surg 1998;228:35-39.

  9. 9. Malmaeus J, Akre T. Adami HO, Hagberg H. Early postoperative course of following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. Br J Surg 1986;73:720-723.

  10. 10. Dawson AA, Jones PI, King DJ. Splenectomy in the management of hematological disease. Br J Surg 1987;74:353-357.

  11. 11. Ellison EG, Fabri PJ. Complications of splenectomy: etiology, prevention and management. Surg Clin North Am 1983;63:1313-1330.

  12. 12. Johanson T, Bostrom H, Sjodahl R, Ihse I. Splenectomy for haematological diseases. Acta Chir Scand 1990;156:83-86.

  13. 13. Sandusky WR, Leavell BS, Benjamín BI. Splenectomy: indications and results in hematologic disorders. Ann Surg 1964;159:695-709.

  14. 14. Wilhem MC, Jones RE, McGehee R, et al. Splenectomy in haematologic disorder: the ever-changing indications. Ann Surg 1988;207:581-589.

  15. 15. Damester HL, Ellis LD. Hematologic indications for splenectomy. Surg Clin North Am 1975;55:253-275.

  16. 16. Musser G, Lasar G, Hocking W, Busettil RW. Splenectomy for hematological disease. Ann Surg 1984;200:40-45.

  17. 17. Nies BA, Creger WP. Tolerance of chemotherapy following splenectomy for leukopenia or thrombocytopenia in patients with malignant lymphomas. Cancer 1967;29:558-562.

  18. 18. Gill PG, Souter RG, Morris PJ. Splenectomy for hypersplenism in malignant lymphomas. Br J Surg 1981;68:29-33.

  19. 19. Thomas JP, Porcell A, Arthur LS. Splenic angiosarcoma and iron deficiency anemia in a 43-year-old man. South Med J 2001;94:640-643.

  20. 20. Tura S, Fiacchini M, Zinzani PL, et al. Splenectomy and the increasing risk of secondary acute leucemia in Hodgkin’s disease. J Clin Oncol 1993;11:925-930.

  21. 21. Swerdlow AJ, Douglas AJ, Vaughan-Hudson G, et al. Risk of secondary primary cancer after Hodgkin disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin disease, and splenectomy. Br J Cancer 1993;68:1005-1111.

  22. 22. Mellemkjoer L, Olson JH, Linet MS, et al. Cancer risk after splenectomy. Cancer 1995;75:577-583.

  23. 23. Salvagno L, Timorato L, Soraru M, et al. Secondary leukemia following treatment for Hodgkin disease. Tumori 1993;79:103-107.

  24. 24. Dietrich PY, Henry-Amar M, Cossel JM, et al. Secondary primary cancers in patients continuously disease-free from Hodgkin disease: a prospective role for the spleen? Blood 1994;84:1209-1215.

>Journals >Cirugía y Cirujanos >Year 2007, Issue 3

· Journal Index 
· Links 
Copyright 2010